Fig. 2From: Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regenerationRecent trends in clinical trials using MSCs. Proportion of country (a), disease conditions (b), autologous or allogeneic (c), and tissue origin of MSCs (d) in recent clinical trialsBack to article page